CL2013001054A1 - Compuestos derivados de cianopirazoles, moduladores de la actividad del receptor gpr119 acoplado a la proteina g; composicion farmaceutica; y metodo para tratar una enfermedad, afeccion, o trastorno metabolico seleccionado de hiperlipidemia, diabetes tipo i, diabetes mellitus tipo ii, diabetes tipo i idiopatica, entre otras. - Google Patents
Compuestos derivados de cianopirazoles, moduladores de la actividad del receptor gpr119 acoplado a la proteina g; composicion farmaceutica; y metodo para tratar una enfermedad, afeccion, o trastorno metabolico seleccionado de hiperlipidemia, diabetes tipo i, diabetes mellitus tipo ii, diabetes tipo i idiopatica, entre otras.Info
- Publication number
- CL2013001054A1 CL2013001054A1 CL2013001054A CL2013001054A CL2013001054A1 CL 2013001054 A1 CL2013001054 A1 CL 2013001054A1 CL 2013001054 A CL2013001054 A CL 2013001054A CL 2013001054 A CL2013001054 A CL 2013001054A CL 2013001054 A1 CL2013001054 A1 CL 2013001054A1
- Authority
- CL
- Chile
- Prior art keywords
- type
- diabetes
- cyanopyrazoles
- hyperlipidemia
- modulators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41644110P | 2010-11-23 | 2010-11-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2013001054A1 true CL2013001054A1 (es) | 2013-09-27 |
Family
ID=45418722
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2013001054A CL2013001054A1 (es) | 2010-11-23 | 2013-04-16 | Compuestos derivados de cianopirazoles, moduladores de la actividad del receptor gpr119 acoplado a la proteina g; composicion farmaceutica; y metodo para tratar una enfermedad, afeccion, o trastorno metabolico seleccionado de hiperlipidemia, diabetes tipo i, diabetes mellitus tipo ii, diabetes tipo i idiopatica, entre otras. |
Country Status (26)
Country | Link |
---|---|
EP (1) | EP2643310A1 (ja) |
JP (1) | JP2013543885A (ja) |
KR (1) | KR20130083915A (ja) |
CN (1) | CN103298801A (ja) |
AP (1) | AP2013006809A0 (ja) |
AR (1) | AR088121A1 (ja) |
AU (1) | AU2011333427A1 (ja) |
BR (1) | BR112013011865A2 (ja) |
CA (1) | CA2814231A1 (ja) |
CL (1) | CL2013001054A1 (ja) |
CO (1) | CO6801716A2 (ja) |
CR (1) | CR20130139A (ja) |
CU (1) | CU20130059A7 (ja) |
DO (1) | DOP2013000102A (ja) |
EA (1) | EA201370118A1 (ja) |
EC (1) | ECSP13012630A (ja) |
GT (1) | GT201300135A (ja) |
MA (1) | MA34805B1 (ja) |
MX (1) | MX2013004083A (ja) |
NI (1) | NI201300044A (ja) |
PE (1) | PE20140409A1 (ja) |
SG (1) | SG189830A1 (ja) |
TW (1) | TWI433843B (ja) |
UY (1) | UY33742A (ja) |
WO (1) | WO2012069948A1 (ja) |
ZA (1) | ZA201302362B (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101913619B1 (ko) | 2011-06-09 | 2018-12-28 | 리젠 파마슈티컬스 소시에떼 아노님 | Gpr-119의 조절제로서의 신규한 화합물 |
AR091739A1 (es) | 2012-07-11 | 2015-02-25 | Elcelyx Therapeutics Inc | Composiciones y metodos para reducir el riesgo cardiometabolico |
JP2017119628A (ja) * | 2014-05-09 | 2017-07-06 | 日産化学工業株式会社 | 置換アゾール化合物及び糖尿病治療薬 |
CN104610151A (zh) * | 2015-02-13 | 2015-05-13 | 佛山市赛维斯医药科技有限公司 | 含酰肼和烷氧苯类结构的化合物、其制备方法及用途 |
CN104592120A (zh) * | 2015-02-13 | 2015-05-06 | 佛山市赛维斯医药科技有限公司 | 一种环丙基酰肼和甲氧苯类gpr119激动剂、制备方法及其用途 |
CN104892517A (zh) * | 2015-02-13 | 2015-09-09 | 佛山市赛维斯医药科技有限公司 | 酰肼类化合物、其制备方法及用途 |
US10874104B2 (en) | 2016-02-18 | 2020-12-29 | Syngenta Participations Ag | Pesticidally active pryazole derivatives |
CN106631992B (zh) * | 2017-01-05 | 2019-01-18 | 桑迪亚医药技术(上海)有限责任公司 | 一种4-氧-3,4-二氢-2h-吡啶-1-甲酸叔丁酯的合成方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101754962B (zh) * | 2007-07-19 | 2013-12-25 | 赛马拜制药公司 | 作为rup3或gpr119受体的激动剂治疗糖尿病和代谢性病症的n-氮杂环状经取代吡咯、吡唑、咪唑、三唑和四唑衍生物 |
DK2280704T3 (en) * | 2008-03-31 | 2015-06-29 | Cymabay Therapeutics Inc | Oxymethylenarylforbindelser and uses thereof |
CN102459222B (zh) * | 2009-06-05 | 2014-06-04 | 辉瑞大药厂 | 用作gpr119 调节剂的l-(哌啶-4-基)-吡唑衍生物 |
-
2011
- 2011-11-09 EP EP11802149.2A patent/EP2643310A1/en not_active Withdrawn
- 2011-11-09 CA CA2814231A patent/CA2814231A1/en not_active Abandoned
- 2011-11-09 EA EA201370118A patent/EA201370118A1/ru unknown
- 2011-11-09 KR KR1020137013064A patent/KR20130083915A/ko not_active Application Discontinuation
- 2011-11-09 BR BR112013011865A patent/BR112013011865A2/pt not_active IP Right Cessation
- 2011-11-09 PE PE2013001058A patent/PE20140409A1/es not_active Application Discontinuation
- 2011-11-09 WO PCT/IB2011/054996 patent/WO2012069948A1/en active Application Filing
- 2011-11-09 AU AU2011333427A patent/AU2011333427A1/en not_active Abandoned
- 2011-11-09 AP AP2013006809A patent/AP2013006809A0/xx unknown
- 2011-11-09 JP JP2013540458A patent/JP2013543885A/ja active Pending
- 2011-11-09 MX MX2013004083A patent/MX2013004083A/es unknown
- 2011-11-09 CN CN2011800550665A patent/CN103298801A/zh active Pending
- 2011-11-09 MA MA35928A patent/MA34805B1/fr unknown
- 2011-11-09 SG SG2013023189A patent/SG189830A1/en unknown
- 2011-11-21 UY UY0001033742A patent/UY33742A/es unknown
- 2011-11-22 AR ARP110104351A patent/AR088121A1/es not_active Application Discontinuation
- 2011-11-22 TW TW100142804A patent/TWI433843B/zh not_active IP Right Cessation
-
2013
- 2013-03-22 CR CR20130139A patent/CR20130139A/es unknown
- 2013-04-02 ZA ZA2013/02362A patent/ZA201302362B/en unknown
- 2013-04-16 CL CL2013001054A patent/CL2013001054A1/es unknown
- 2013-04-23 CU CU2013000059A patent/CU20130059A7/es unknown
- 2013-05-09 DO DO2013000102A patent/DOP2013000102A/es unknown
- 2013-05-13 NI NI201300044A patent/NI201300044A/es unknown
- 2013-05-20 EC ECSP13012630 patent/ECSP13012630A/es unknown
- 2013-05-21 GT GT201300135A patent/GT201300135A/es unknown
- 2013-05-23 CO CO13127143A patent/CO6801716A2/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
DOP2013000102A (es) | 2013-07-15 |
MX2013004083A (es) | 2013-06-13 |
EA201370118A1 (ru) | 2013-12-30 |
TW201300373A (zh) | 2013-01-01 |
TWI433843B (zh) | 2014-04-11 |
UY33742A (es) | 2012-06-29 |
PE20140409A1 (es) | 2014-03-23 |
EP2643310A1 (en) | 2013-10-02 |
ZA201302362B (en) | 2014-06-25 |
GT201300135A (es) | 2015-02-19 |
CR20130139A (es) | 2013-06-28 |
AR088121A1 (es) | 2014-05-14 |
ECSP13012630A (es) | 2013-07-31 |
NI201300044A (es) | 2013-08-01 |
BR112013011865A2 (pt) | 2016-08-23 |
CA2814231A1 (en) | 2012-05-31 |
JP2013543885A (ja) | 2013-12-09 |
CN103298801A (zh) | 2013-09-11 |
MA34805B1 (fr) | 2014-01-02 |
SG189830A1 (en) | 2013-06-28 |
KR20130083915A (ko) | 2013-07-23 |
AU2011333427A1 (en) | 2013-04-11 |
AP2013006809A0 (en) | 2013-04-30 |
CU20130059A7 (es) | 2013-06-28 |
CO6801716A2 (es) | 2013-11-29 |
WO2012069948A1 (en) | 2012-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2013001054A1 (es) | Compuestos derivados de cianopirazoles, moduladores de la actividad del receptor gpr119 acoplado a la proteina g; composicion farmaceutica; y metodo para tratar una enfermedad, afeccion, o trastorno metabolico seleccionado de hiperlipidemia, diabetes tipo i, diabetes mellitus tipo ii, diabetes tipo i idiopatica, entre otras. | |
CL2008002110A1 (es) | Procedimiento para la modulacion del receptor acoplado a la proteina g gpr119 para administrar un compuesto derivado de piridinona y opcionalmente un agente terapeutico opcional para tratar diabetes mellitus. | |
EA201001329A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
SMT201600216B (it) | Ottaidropirrolo[3,4.c]pirroli disostituiti come modulatori del recettore di orexina | |
CL2013000716A1 (es) | Un profarmaco o una sal del mismo que comprende un conjugado de exendina-conector; procedimiento de preparacion de dicho profarmaco; compuestos intermediarios; composicion farmaceutica que lo comprende, util para mejorar el control glucemico en pacientes con diabetes de tipo 2. | |
CL2013000787A1 (es) | Compuestos derivados de benzamida fusionada sustituida, moduladores del receptor de bradiquininas; composición farmaceutica, utiles en el tratamiento del dolor agudo, visceral, neuropatico, inflamacion de la piel, entre otras. | |
EA201391764A1 (ru) | Агонисты рецептора glp-1/глюкагона длительного действия | |
EA201001332A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
CL2013003598A1 (es) | Compuestos derivados de benzooxazepinona, moduladores de canales de sodio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades seleccionadas de arritmias, insuficiencia cardiaca, angina, infarto al miocardio, diabetes, entre otras | |
CL2010001496A1 (es) | Compuestos derivados de (piridin-o pirimidin-)piperidina, agonistas de gpr119; composicion farmaceutica; y su uso para el tratamiento de la diabetes de tipo i, diabetes de tipo ii y enfermedades relacionadas tales como sindrome metabolico, dislipidemia y resistencia a la insulina. | |
CL2008000198A1 (es) | Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, trastorno de lipidos, obesidad y aterosclerosis. | |
CL2013000714A1 (es) | Compuestos derivados de lactamas sustituidas con piperidinilo, moduladores de gpr119; proceso de preparacion; composicion farmaceutica que los comprende; metodo de tratamiento; y uso del compuesto para tratar enfermedades tales como diabetes tipo 2, sindrome metabolico, dislipidemia, hipertension y esquizofrenia, entre otras. | |
CL2008000690A1 (es) | Compuestos derivados del acido indol-3-propionico; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hiperlipidemia, hipertension; entre otras. | |
EA201001330A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
CL2007002348A1 (es) | Compuestos heterociclicos, moduladores de la actividad de la estearoil-coa-desaturasa; composicion farmaceutica, util para el tratamiento de enfermedades tales como diabetes, dislipidemias, obesidad, anorexia y acne. | |
CL2013002414A1 (es) | Compuestos derivados de azabencimidazol ciclico, activadores de la proteina cinasa activada por amp; composicion farmaceutica que los comprende; y su uso para el tratamiento o enfermedad tal como diabetes tipo 2, hiperglicemia, sindrome metabolico, obesidad, hipercolesterolemia e hipertension. | |
CL2013003372A1 (es) | Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes. | |
CL2013002053A1 (es) | Compuestos derivados de heterociclicos, antagonistas del receptor de glucagon; composicion farmaceutica que lo comprende y su uso en el tratamiento de diabetes y enfermedades metabolicas. pct | |
EA201290964A1 (ru) | Пептидные конъюгаты агонистов рецептора glp-1 и их применение | |
BR112012004333A2 (pt) | composto, composição farmacêutica, e, método para o tratamento ou a prevenção de uma doença ou um distúrbio. | |
BRPI1008145A2 (pt) | proteína de ligação de antígeno biespecífico, método para preparação de uma proteína de ligação de antígeno biespecífico, célula hospedeira, composição farmacêutica, uso da proteína de ligação de antígeno biespecífico e método para o tratamento de um paciente. | |
CL2013001104A1 (es) | Composicion farmaceutica que comprende un inhibidor de sglt2 y una insulina; y uso para tratar una enfermedad o afeccion tal como diabetes mellitus, diabetes mellitus tipo 1 y 2, entre otras. | |
BRPI0915382A2 (pt) | composto, composição farmacêutica, e, método para tratar uma doença ou um distúrbio. | |
BRPI0813456A2 (pt) | Composto, uso do mesmo, composição farmacêutica, e, métodos para tratar um mamífero sofrendo de um distúrbio e de uma doença | |
CL2008000403A1 (es) | Compuestos derivados de pentafluorotiobenzamido-acetonitrilo; composicion farmaceutica; y uso para tratar una infestacion por parasitos. |